Zhejiang Medicine Co Ltd
SSE:600216
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Medicine Co Ltd
Other Current Liabilities
Zhejiang Medicine Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Zhejiang Medicine Co Ltd
SSE:600216
|
Other Current Liabilities
¥496.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
25%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Liabilities
¥4B
|
CAGR 3-Years
106%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Liabilities
¥3.9B
|
CAGR 3-Years
126%
|
CAGR 5-Years
12%
|
CAGR 10-Years
24%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Liabilities
¥3.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
10%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Other Current Liabilities
¥919.3m
|
CAGR 3-Years
52%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Liabilities
¥435.5m
|
CAGR 3-Years
74%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
Zhejiang Medicine Co Ltd
Glance View
Zhejiang Medicine Co., Ltd., a stalwart in the pharmaceutical industry, traces its roots back to a time when China's economic landscape was rapidly transforming. Founded amidst the burgeoning wave of Chinese industrial expansion, the company made a calculated entry into the biopharmaceutical sector, a move that positioned it as an indispensable player in the realm of vitamins and antibiotics. Headquartered in the populous province of Zhejiang, the firm quickly honed its expertise in the manufacturing and export of fat-soluble vitamins, notably vitamin E, which became one of its hallmark products. Their robust production facilities and rigorous adherence to quality standards have not only fueled domestic demand but also secured a strong foothold in international markets, particularly Europe and the Americas. Zhejiang Medicine has crafted a diversified portfolio that spans active pharmaceutical ingredients (APIs) and advanced intermediates, offering a spectrum of products utilized by various health and pharmaceutical companies worldwide. A key revenue driver for the company lies in its vertical integration strategy, which enables it to maintain meticulous oversight over the entire production process, from raw materials to finished goods. The company’s commitment to R&D is evident in its investments in technology and innovation, allowing it to improve production efficiency and develop new compounds that cater to the evolving demands of the health sector. This approach not only insulates the company from market volatility but also fortifies its competitive position in a dynamic industry.
See Also
What is Zhejiang Medicine Co Ltd's Other Current Liabilities?
Other Current Liabilities
496.4m
CNY
Based on the financial report for Dec 31, 2025, Zhejiang Medicine Co Ltd's Other Current Liabilities amounts to 496.4m CNY.
What is Zhejiang Medicine Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
25%
Over the last year, the Other Current Liabilities growth was -8%. The average annual Other Current Liabilities growth rates for Zhejiang Medicine Co Ltd have been -5% over the past three years , -1% over the past five years , and 25% over the past ten years .